13 The primary endpoint of progression-free survival (PFS) was highly significant in favour of the lanreotide arm, with a PFS of 18 months in the placebo arm and not reached in the experimental cohort (HR: 0.47, 95% CI: 0.30 to 0.73).
1
—
—
13 The primary endpoint of progression-free survival (PFS) was highly significant in favour of the lanreotide arm, with a PFS of 18 months in the placebo arm and not reached in the experimental cohort (HR: 0.47, 95% CI: 0.30 to 0.73).